Call Options

14 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2022

Feb 14, 2023

SELL
$0.49 - $0.57 $2,989 - $3,476
-6,100 Reduced 31.12%
13,500 $7,000
Q3 2022

Nov 14, 2022

SELL
$0.49 - $1.95 $24,892 - $99,060
-50,800 Reduced 72.16%
19,600 $10,000
Q2 2022

Aug 15, 2022

SELL
$0.36 - $1.78 $41,904 - $207,192
-116,400 Reduced 62.31%
70,400 $125,000
Q3 2021

Nov 15, 2021

BUY
$3.78 - $5.18 $647,136 - $886,816
171,200 Added 1097.44%
186,800 $768,000
Q2 2021

Aug 11, 2021

SELL
$4.1 - $5.33 $310,780 - $404,014
-75,800 Reduced 82.93%
15,600 $68,000
Q1 2021

May 17, 2021

BUY
$4.93 - $7.15 $370,736 - $537,680
75,200 Added 464.2%
91,400 $461,000
Q4 2020

Feb 16, 2021

BUY
$4.55 - $7.29 $22,750 - $36,450
5,000 Added 44.64%
16,200 $102,000
Q3 2020

Nov 16, 2020

SELL
$4.22 - $6.04 $178,928 - $256,096
-42,400 Reduced 79.1%
11,200 $48,000
Q1 2020

May 15, 2020

BUY
$3.5 - $8.51 $5,950 - $14,467
1,700 Added 3.28%
53,600 $234,000
Q1 2019

May 15, 2019

SELL
$7.67 - $9.96 $88,972 - $115,536
-11,600 Reduced 18.27%
51,900 $421,000
Q4 2018

Feb 14, 2019

BUY
$6.59 - $11.28 $264,918 - $453,456
40,200 Added 172.53%
63,500 $501,000
Q3 2018

Nov 14, 2018

SELL
$9.35 - $12.44 $954,635 - $1.27 Million
-102,100 Reduced 81.42%
23,300 $251,000
Q2 2018

Aug 14, 2018

BUY
$9.11 - $28.88 $585,773 - $1.86 Million
64,300 Added 105.24%
125,400 $1.46 Million
Q1 2018

May 15, 2018

BUY
$14.18 - $35.6 $866,398 - $2.18 Million
61,100 New
61,100 $1.58 Million

Others Institutions Holding CBIO

# of Institutions
1
Shares Held
215
Call Options Held
0
Put Options Held
0

About CATALYST BIOSCIENCES, INC.


  • Ticker CBIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,477,100
  • Description
  • Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB ...
More about CBIO
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.